{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:22:01Z","timestamp":1792714921587,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-021-08916-8","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T14:07:16Z","timestamp":1641996436000},"page":"75-89","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Future of Therapy for Inborn Errors of Immunity"],"prefix":"10.1007","volume":"63","author":[{"given":"Elena","family":"Perez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,12]]},"reference":[{"issue":"1","key":"8916_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s10875-019-00737-x","volume":"40","author":"SG Tangye","year":"2020","unstructured":"Tangye SG, Al-Herz W, Bousfiha A et al (2020) Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 40(1):24\u201364. https:\/\/doi.org\/10.1007\/s10875-019-00737-x","journal-title":"J Clin Immunol"},{"issue":"Suppl 26","key":"8916_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/pai.13365","volume":"31","author":"R Castagnoli","year":"2020","unstructured":"Castagnoli R, Notarangelo LD (2020) Updates on new monogenic inborn errors of immunity. Pediatr Allergy Immunol 31(Suppl 26):57\u201359. https:\/\/doi.org\/10.1111\/pai.13365","journal-title":"Pediatr Allergy Immunol"},{"issue":"2","key":"8916_CR3","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jaip.2020.11.044","volume":"9","author":"RS Abraham","year":"2021","unstructured":"Abraham RS, Butte MJ (2021) The new \u201cwholly trinity\u201d in the diagnosis and management of inborn errors of immunity. J Allergy Clin Immunol Pract 9(2):613\u2013625. https:\/\/doi.org\/10.1016\/j.jaip.2020.11.044","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8916_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.02.006","author":"JE Hale","year":"2021","unstructured":"Hale JE, Platt CD, Bonilla FA et al (2021) Ten years of newborn screening for severe combined immunodeficiency (SCID) in Massachusetts. J Allergy Clin Immunol Pract. https:\/\/doi.org\/10.1016\/j.jaip.2021.02.006","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"8916_CR5","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jaip.2018.12.022","volume":"7","author":"J Heimall","year":"2019","unstructured":"Heimall J (2019) Now is the time to use molecular gene testing for the diagnosis of primary immune deficiencies. J Allergy Clin Immunol Pract 7(3):833\u2013838. https:\/\/doi.org\/10.1016\/j.jaip.2018.12.022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8916_CR6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3389\/fped.2019.00353","volume":"7","author":"OM Delmonte","year":"2019","unstructured":"Delmonte OM, Castagnoli R, Calzoni E, Notarangelo LD (2019) Inborn errors of immunity with immune dysregulation: from bench to bedside. Front Pediatr 7:353. https:\/\/doi.org\/10.3389\/fped.2019.00353","journal-title":"Front Pediatr"},{"issue":"5","key":"8916_CR7","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","volume":"77","author":"S Banerjee","year":"2017","unstructured":"Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM (2017) JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs 77(5):521\u2013546. https:\/\/doi.org\/10.1007\/s40265-017-0701-9","journal-title":"Drugs"},{"issue":"5","key":"8916_CR8","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.jaci.2018.07.020","volume":"142","author":"LR Forbes","year":"2018","unstructured":"Forbes LR, Vogel TP, Cooper MA et al (2018) Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. J Allergy Clin Immunol 142(5):1665\u20131669. https:\/\/doi.org\/10.1016\/j.jaci.2018.07.020","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"8916_CR9","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/emmm.201201379","volume":"4","author":"DM Czajkowsky","year":"2012","unstructured":"Czajkowsky DM, Hu J, Shao Z, Pleass RJ (2012) Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med 4(10):1015\u20131028. https:\/\/doi.org\/10.1002\/emmm.201201379","journal-title":"EMBO Mol Med"},{"issue":"2 Suppl 2","key":"8916_CR10","doi-asserted-by":"publisher","first-page":"S314","DOI":"10.1016\/j.jaci.2009.08.018","volume":"125","author":"SJ Lee","year":"2010","unstructured":"Lee SJ, Chinen J, Kavanaugh A (2010) Immunomodulator therapy: monoclonal antibodies, fusion proteins, cytokines, and immunoglobulins. J Allergy Clin Immunol 125(2 Suppl 2):S314\u2013S323. https:\/\/doi.org\/10.1016\/j.jaci.2009.08.018","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"8916_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s10875-012-9755-3","volume":"33","author":"NM Chase","year":"2013","unstructured":"Chase NM, Verbsky JW, Hintermeyer MK et al (2013) Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID). J Clin Immunol 33(1):30\u201339. https:\/\/doi.org\/10.1007\/s10875-012-9755-3","journal-title":"J Clin Immunol"},{"issue":"2","key":"8916_CR12","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jaci.2020.07.021","volume":"147","author":"JW Verbsky","year":"2021","unstructured":"Verbsky JW, Hintermeyer MK, Simpson PM et al (2021) Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency. J Allergy Clin Immunol 147(2):704-712 e17. https:\/\/doi.org\/10.1016\/j.jaci.2020.07.021","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"8916_CR13","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1016\/j.jaip.2019.07.026","volume":"7","author":"JW Leiding","year":"2019","unstructured":"Leiding JW, Ballow M (2019) Redefining precision medicine in disorders of immune dysregulation. J Allergy Clin Immunol Pract 7(8):2801\u20132803. https:\/\/doi.org\/10.1016\/j.jaip.2019.07.026","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"Suppl 24","key":"8916_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/pai.13163","volume":"31","author":"OM Delmonte","year":"2020","unstructured":"Delmonte OM (2020) Immunodeficiency and disorders of immune dysregulation. Pediatr Allergy Immunol 31(Suppl 24):8\u201310. https:\/\/doi.org\/10.1111\/pai.13163","journal-title":"Pediatr Allergy Immunol"},{"issue":"3","key":"8916_CR15","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jaip.2018.12.017","volume":"7","author":"JW Leiding","year":"2019","unstructured":"Leiding JW, Forbes LR (2019) Mechanism-based precision therapy for the treatment of primary immunodeficiency and primary immunodysregulatory diseases. J Allergy Clin Immunol Pract 7(3):761\u2013773. https:\/\/doi.org\/10.1016\/j.jaip.2018.12.017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"8916_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/cei.12178","volume":"174","author":"R Ameratunga","year":"2013","unstructured":"Ameratunga R, Woon ST, Gillis D, Koopmans W, Steele R (2013) New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin. Clin Exp Immunol 174(2):203\u2013211. https:\/\/doi.org\/10.1111\/cei.12178","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"8916_CR17","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/eji.202048713","volume":"50","author":"L Hanitsch","year":"2020","unstructured":"Hanitsch L, Baumann U, Boztug K et al (2020) Treatment and management of primary antibody deficiency: German interdisciplinary evidence-based consensus guideline. Eur J Immunol 50(10):1432\u20131446. https:\/\/doi.org\/10.1002\/eji.202048713","journal-title":"Eur J Immunol"},{"issue":"3","key":"8916_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/cei.12915","volume":"188","author":"S Jolles","year":"2017","unstructured":"Jolles S, Chapel H, Litzman J (2017) When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach. Clin Exp Immunol 188(3):333\u2013341. https:\/\/doi.org\/10.1111\/cei.12915","journal-title":"Clin Exp Immunol"},{"issue":"3S","key":"8916_CR19","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","volume":"139","author":"EE Perez","year":"2017","unstructured":"Perez EE, Orange JS, Bonilla F et al (2017) Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol 139(3S):S1\u2013S46. https:\/\/doi.org\/10.1016\/j.jaci.2016.09.023","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"8916_CR20","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.iac.2015.07.006","volume":"35","author":"P Sriaroon","year":"2015","unstructured":"Sriaroon P, Ballow M (2015) Immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am 35(4):713\u2013730. https:\/\/doi.org\/10.1016\/j.iac.2015.07.006","journal-title":"Immunol Allergy Clin North Am"},{"issue":"8","key":"8916_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11882-016-0632-7","volume":"16","author":"L Yang","year":"2016","unstructured":"Yang L, Wu EY, Tarrant TK (2016) Immune gamma globulin therapeutic indications in immune deficiency and autoimmunity. Curr Allergy Asthma Rep 16(8):55. https:\/\/doi.org\/10.1007\/s11882-016-0632-7","journal-title":"Curr Allergy Asthma Rep"},{"issue":"Suppl 2","key":"8916_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1365-2249.2011.04390.x","volume":"164","author":"C Cunningham-Rundles","year":"2011","unstructured":"Cunningham-Rundles C (2011) Key aspects for successful immunoglobulin therapy of primary immunodeficiencies. Clin Exp Immunol 164(Suppl 2):16\u201319. https:\/\/doi.org\/10.1111\/j.1365-2249.2011.04390.x","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"8916_CR23","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/cei.12485","volume":"179","author":"S Jolles","year":"2015","unstructured":"Jolles S, Orange JS, Gardulf A et al (2015) Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clin Exp Immunol 179(2):146\u2013160. https:\/\/doi.org\/10.1111\/cei.12485","journal-title":"Clin Exp Immunol"},{"key":"8916_CR24","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.3389\/fimmu.2018.01925","volume":"9","author":"JD Langereis","year":"2018","unstructured":"Langereis JD, van der Flier M, de Jonge MI (2018) Limited innovations after more than 65 years of immunoglobulin replacement therapy: potential of IgA- and IgM-enriched formulations to prevent bacterial respiratory tract infections. Front Immunol 9:1925. https:\/\/doi.org\/10.3389\/fimmu.2018.01925","journal-title":"Front Immunol"},{"issue":"1\u20132","key":"8916_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000510251","volume":"106","author":"D Sterlin","year":"2021","unstructured":"Sterlin D, Gorochov G (2021) When therapeutic IgA antibodies might come of age. Pharmacology 106(1\u20132):9\u201319. https:\/\/doi.org\/10.1159\/000510251","journal-title":"Pharmacology"},{"issue":"3","key":"8916_CR26","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jaip.2018.10.049","volume":"7","author":"KM Harris","year":"2019","unstructured":"Harris KM, Davila BJ, Bollard CM, Keller MD (2019) Virus-specific T cells: current and future use in primary immunodeficiency disorders. J Allergy Clin Immunol Pract 7(3):809\u2013818. https:\/\/doi.org\/10.1016\/j.jaip.2018.10.049","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8916_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3389\/fimmu.2020.00239","volume":"11","author":"AY Chan","year":"2020","unstructured":"Chan AY, Leiding JW, Liu X et al (2020) Hematopoietic cell transplantation in patients with primary immune regulatory disorders (PIRD): a primary immune deficiency treatment consortium (PIDTC) survey. Front Immunol 11:239. https:\/\/doi.org\/10.3389\/fimmu.2020.00239","journal-title":"Front Immunol"},{"key":"8916_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3389\/fped.2019.00295","volume":"7","author":"R Castagnoli","year":"2019","unstructured":"Castagnoli R, Delmonte OM, Calzoni E, Notarangelo LD (2019) Hematopoietic Stem Cell Transplantation in primary immunodeficiency diseases: current status and future perspectives. Front Pediatr 7:295. https:\/\/doi.org\/10.3389\/fped.2019.00295","journal-title":"Front Pediatr"},{"key":"8916_CR29","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.3389\/fimmu.2019.01570","volume":"10","author":"R Greco","year":"2019","unstructured":"Greco R, Labopin M, Badoglio M et al (2019) Allogeneic HSCT for autoimmune diseases: a retrospective study from the EBMT ADWP, IEWP, and PDWP working parties. Front Immunol 10:1570. https:\/\/doi.org\/10.3389\/fimmu.2019.01570","journal-title":"Front Immunol"},{"key":"8916_CR30","doi-asserted-by":"publisher","unstructured":"Aiuti A, Roncarolo MG (2009) Ten years of gene therapy for primary immune deficiencies. Hematology Am Soc Hematol Educ Program 682\u20139. https:\/\/doi.org\/10.1182\/asheducation-2009.1.682","DOI":"10.1182\/asheducation-2009.1.682"},{"issue":"6","key":"8916_CR31","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/MOP.0b013e32834cd67a","volume":"23","author":"C Booth","year":"2011","unstructured":"Booth C, Gaspar HB, Thrasher AJ (2011) Gene therapy for primary immunodeficiency. Curr Opin Pediatr 23(6):659\u2013666. https:\/\/doi.org\/10.1097\/MOP.0b013e32834cd67a","journal-title":"Curr Opin Pediatr"},{"issue":"R1","key":"8916_CR32","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1093\/hmg\/ddz170","volume":"28","author":"C Booth","year":"2019","unstructured":"Booth C, Romano R, Roncarolo MG, Thrasher AJ (2019) Gene therapy for primary immunodeficiency. Hum Mol Genet 28(R1):R15\u2013R23. https:\/\/doi.org\/10.1093\/hmg\/ddz170","journal-title":"Hum Mol Genet"},{"key":"8916_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.12.010","author":"H Bloomer","year":"2020","unstructured":"Bloomer H, Smith RH, Hakami W, Larochelle A (2020) Genome editing in human hematopoietic stem and progenitor cells via CRISPR-Cas9-mediated homology-independent targeted integration. Mol Ther. https:\/\/doi.org\/10.1016\/j.ymthe.2020.12.010","journal-title":"Mol Ther"},{"issue":"3","key":"8916_CR34","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1042\/ETLS20180157","volume":"3","author":"SS De Ravin","year":"2019","unstructured":"De Ravin SS, Brault J (2019) CRISPR\/Cas9 applications in gene therapy for primary immunodeficiency diseases. Emerg Top Life Sci 3(3):277\u2013287. https:\/\/doi.org\/10.1042\/ETLS20180157","journal-title":"Emerg Top Life Sci"},{"issue":"1","key":"8916_CR35","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000509","volume":"5","author":"BC Houghton","year":"2021","unstructured":"Houghton BC, Booth C (2021) Gene therapy for primary immunodeficiency. Hemasphere 5(1):e509. https:\/\/doi.org\/10.1097\/HS9.0000000000000509","journal-title":"Hemasphere"},{"issue":"3","key":"8916_CR36","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jaci.2017.01.007","volume":"139","author":"DB Kohn","year":"2017","unstructured":"Kohn DB, Kuo CY (2017) New frontiers in the therapy of primary immunodeficiency: from gene addition to gene editing. J Allergy Clin Immunol 139(3):726\u2013732. https:\/\/doi.org\/10.1016\/j.jaci.2017.01.007","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"8916_CR37","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.gendis.2019.07.007","volume":"7","author":"ZY Zhang","year":"2020","unstructured":"Zhang ZY, Thrasher AJ, Zhang F (2020) Gene therapy and genome editing for primary immunodeficiency diseases. Genes Dis 7(1):38\u201351. https:\/\/doi.org\/10.1016\/j.gendis.2019.07.007","journal-title":"Genes Dis"},{"issue":"11","key":"8916_CR38","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1089\/hum.2017.175","volume":"28","author":"F Ferrua","year":"2017","unstructured":"Ferrua F, Aiuti A (2017) Twenty-five years of gene therapy for ADA-SCID: from bubble babies to an approved drug. Hum Gene Ther 28(11):972\u2013981. https:\/\/doi.org\/10.1089\/hum.2017.175","journal-title":"Hum Gene Ther"},{"key":"8916_CR39","doi-asserted-by":"publisher","unstructured":"Fischer A, Hacein-Bey-Abina S (2020). Gene therapy for severe combined immunodeficiencies and beyond. J Exp Med 217(2). https:\/\/doi.org\/10.1084\/jem.20190607","DOI":"10.1084\/jem.20190607"},{"issue":"6","key":"8916_CR40","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41573-019-0020-9","volume":"18","author":"M Cavazzana","year":"2019","unstructured":"Cavazzana M, Bushman FD, Miccio A, Andre-Schmutz I, Six E (2019) Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges. Nat Rev Drug Discov 18(6):447\u2013462. https:\/\/doi.org\/10.1038\/s41573-019-0020-9","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"8916_CR41","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.ymthe.2017.03.018","volume":"25","author":"AJ Thrasher","year":"2017","unstructured":"Thrasher AJ, Williams DA (2017) Evolving gene therapy in primary immunodeficiency. Mol Ther 25(5):1132\u20131141. https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.018","journal-title":"Mol Ther"},{"issue":"6","key":"8916_CR42","doi-asserted-by":"publisher","first-page":"737","DOI":"10.15252\/emmm.201707573","volume":"9","author":"A Aiuti","year":"2017","unstructured":"Aiuti A, Roncarolo MG, Naldini L (2017) Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products. EMBO Mol Med 9(6):737\u2013740. https:\/\/doi.org\/10.15252\/emmm.201707573","journal-title":"EMBO Mol Med"},{"issue":"2","key":"8916_CR43","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jaip.2020.11.055","volume":"9","author":"MA Cooper","year":"2021","unstructured":"Cooper MA, Zimmerman O, Nataraj R, Wynn RF (2021) Lifelong Immune Modulation Versus Hematopoietic cell therapy for inborn errors of immunity. J Allergy Clin Immunol Pract 9(2):628\u2013639. https:\/\/doi.org\/10.1016\/j.jaip.2020.11.055","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"8916_CR44","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jaip.2020.11.022","volume":"9","author":"PD Arkwright","year":"2021","unstructured":"Arkwright PD, Walter JE (2021) Introducing a new epoch in inborn errors of immunity. J Allergy Clin Immunol Pract 9(2):660\u2013662. https:\/\/doi.org\/10.1016\/j.jaip.2020.11.022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"8916_CR45","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jaci.2020.06.011","volume":"147","author":"KE Sullivan","year":"2021","unstructured":"Sullivan KE (2021) The scary world of variants of uncertain significance (VUS): a hitchhiker\u2019s guide to interpretation. J Allergy Clin Immunol 147(2):492\u2013494. https:\/\/doi.org\/10.1016\/j.jaci.2020.06.011","journal-title":"J Allergy Clin Immunol"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-021-08916-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-021-08916-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-021-08916-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T10:48:29Z","timestamp":1744195709000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-021-08916-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,12]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["8916"],"URL":"https:\/\/doi.org\/10.1007\/s12016-021-08916-8","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,12]]},"assertion":[{"value":"23 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Consultancy work for Takeda, Grifols, CSL Behring; Speaker bureau for Takeda, Genentech, CSL Behring.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest\/Competing Interest"}}]}}